Kezar Life Sciences, Inc. (KZR)
KZRPrice: $6.7
Fair Value: 🔒
🔒score
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunop... more
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and deve... more
Description
Shares
| Market Cap | $49.07M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Christopher J. Kirk |
| IPO Date | 2018-06-21 | CAGR | — |
| Employees | 55 | Website | www.kezarlifesciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KZR chart loading...
Fundamentals
Technicals
| Enterprise Value | $12.22M | P/E Ratio | -0.79 |
| Forward P/E | -2.78 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.76 |
| P/CF Ratio | -1.19 | P/FCF Ratio | -1.21 |
| EPS | $-8.44 | EPS Growth 1Y | 539.39% |
| EPS Growth 3Y | 744% | EPS Growth 5Y | 633.91% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.64% | ROA | -0.65% |
| ROCE | -0.8% | Current Ratio | 7.29 |
| Quick Ratio | 7.29 | Cash Ratio | 2.39 |
| Debt/Equity | 0.1 | Interest Coverage | -52.56 |
| Altman Z Score | -5.4 | Piotroski Score | 3 |